Effect of Trastuzumab combined with GEM and CAP chemotherapy on serum T cell subsets, TPS levels and quality of life in patients with HER-2 positive advanced breast cancer
SHEN Chunyan1 JIN Xiaoxin1 WANG Shuling2
1.Department of Oncology, Affiliated Hospital of Armed Police Logistics College, Tianjin 300162, China;
2.Key Laboratory of Cancer Prevention and Therapy Affiliated Cancer Hospital of Tianjin Medical University, Tianjin 300060, China
Abstract：Objective To investigate the effect of Trastuzumab combined with Gemcitabine (GEM) and Capecitabine (CAP) in advanced breast cancer patients with positive human epidermal growth factor receptor 2 (HER-2). Methods Eighty patients with HER-2 positive advanced breast cancer admitted to the Affiliated Hospital of Armed Police Logistics College from August 2010 to April 2015 were selected. According to the random number table, 40 cases in control group were treated with GEM and CAP, and 40 cases in observation group were treated with Trastuzumab on the basis of control group. The disease control and the levels of serum tumor markers indicators [tissue polypeptide specific antigen (TPS), cancer-related glycoprotein antigen 153 (CA153)] before and after treatment, serum T cell subsets (serum CD3+, CD4+, CD8+) levels and quality of life dimensions (role function, emotional function, cognitive function, physical function, social function) score changes were observed between two groups, the occurrence of toxic and side effects and survival rate were also counted between two groups. Results The clinical efficacy of observation group was better than that of control group, and the disease control rate of observation group was higher than that of control group (P < 0.05). After 2 months of treatment, the levels of serum TPS and CA153 in two groups were lower than those before treatment, and the decrease in observation group was more obvious than that in control group (P < 0.05). After 2 months of treatment, the levels of serum CD3+ and CD4+ in two groups were lower than those before treatment, but the levels in observation group were higher than those in control group (P < 0.05). There was no significant difference in serum CD8+ level between two groups before and after treatment (P ＞ 0.05). There was no significant difference in the incidence of leukopenia, nausea, vomiting and thrombocytopenia between two groups (P ＞ 0.05). The scores of cognitive function, somatic function, role function, emotional function and social function in two groups were higher than those before treatment, and those in observation group were higher than those in control group (P < 0.05). There was no significant difference in 1, 2 and 3-year survival rates between two groups (P ＞ 0.05). Conclusion Trastuzumab combined with GEM and CAP chemotherapy can reduce serum tumor marker levels in patients with HER-2 positive advanced breast cancer, improve the clinical control rate of the disease, have less damage to the patient′s immune function and have a high prognosis survival rate with fewer side effects. It can improve the quality of life of patients.
沈春燕1 金晓新1 王淑玲2. 曲妥珠单抗联合GEM、CAP化疗对HER-2阳性晚期乳腺癌患者血清T细胞亚群、TPS水平及生存质量的影响[J]. 中国医药导报, 2019, 16(19): 93-97.
SHEN Chunyan1 JIN Xiaoxin1 WANG Shuling2. Effect of Trastuzumab combined with GEM and CAP chemotherapy on serum T cell subsets, TPS levels and quality of life in patients with HER-2 positive advanced breast cancer. 中国医药导报, 2019, 16(19): 93-97.
[1] 崔剑锋.曲妥珠单抗联合长春瑞滨治疗HER-2阳性晚期乳腺癌患者的疗效分析[J].实用药物与临床，2017，20（7）：759-762.
[2] Baselga J，Bradbury I，Eidtmann H，et al. Lapatinib with trastuzumab for HER2-positive early breast cancer （Neo- ALTTO）：a randomised，open-label，multicentre，phase 3 trial [J]. Lancet Oncol，2014，15（10）：1137-1146.
[3] 何江涛，王伟.曲妥珠单抗联合吉西他滨或卡培他滨一线治疗HER-2阳性晚期乳腺癌的临床研究[J].中国当代医药，2017，24（13）：97-99.
[4] 胡爱玲.曲妥珠单抗联合含紫杉类方案治疗HER-2阳性晚期乳腺癌疗效观察[J].现代中西医结合杂志，2015，24（35）：3948-3950.
[5] 文芳，翁洁，罗盘.吉西他滨联合卡培他滨二线治疗晚期乳腺癌的疗效评价[J].中国肿瘤外科杂志，2015，7（3）：184-185.
[6] 黄玉琴.注射用曲妥珠单抗对人表皮生长因子受体2阳性晚期乳腺癌化疗患者血清肿瘤标志物及免疫功能的影响[J].中国综合临床，2017，33（8）：748-752.
[7] 王福玲.世界医学会《赫尔辛基宣言》——涉及人类受试者的医学研究的伦理原则[J].中国医学伦理学，2016，29（3）：544-546.
[8] 贾春芳，段敏，段昕.参芪扶正注射液联合化疗治疗乳腺癌的疗效及对患者造血功能及免疫功能的影响[J].海南医学院学报，2016，22（16）：1866-1869.
[9] 唐政，王继伟，张庆云，等.QLQ-BR23和EORTC QLQ-C30测量康复锻炼对乳腺癌患者生命质量的影响[J].复旦学报：医学版，2015，42（5）：589-595.
[10] 廖春雁，陈圆圆，曾健，等.常规超声结合弹性成像对非哺乳期乳腺炎与乳腺癌的鉴别诊断价值[J].中国超声医学杂志，2016，32（1）：16-18.
[11] Weiss NS. Re：“twenty five year follow-up for breast cancer incidence and mortality of the canadian national breast screening study：randomised screening trial” [J]. Am J Epidemiol，2014，180（7）：759-760.
[12] 王俊斌，杨燕，汪子书，等.长春瑞滨或吉西他滨联合顺铂治疗转移性三阴性乳腺癌的临床疗效与安全性评价[J].中国临床药理学杂志，2016，32（1）：24-26.
[13] 熊娟.探讨肿瘤标志物（CA153、CA199、CA125、CEA）联合检测对乳腺癌、卵巢癌和结直肠癌的诊断价值[J].中国社区医师，2017，33（1）：93-94.
[14] 蒋显勇，易艳军，梁庄严，等.血清HER-2/neu、TPS、CA15-3和TSGF联合检测在乳腺癌诊断中的价值[J].实用医学杂志，2016，32（24）：4115-4117.
[15] 傅丽敏，程雪，张小薇.血清肿瘤标记物癌胚抗原、CA153和CA125检测对乳腺癌的临床诊断价值[J].中国现代医生，2016，54（20）：104-107.
[16] 林梅燕，王季堃.卡培他滨和吉西他滨分别联合卡铂治疗晚期三阴性乳腺癌的近期疗效比较[J].解放军医学院学报，2016，37（6）：573-575.
[17] 宋志刚，庞东生，李星缘.卡培他滨联合吉西他滨治疗蒽环类耐药的转移性乳腺癌的效果比较[J].宁夏医科大学学报，2015，37（4）：459-461.
[18] 殷科，曹永晋.曲妥珠单抗新辅助化疗表皮生长因子受体2阳性乳腺癌的临床疗效及安全性评价[J].中国临床药理学杂志，2015，31（9）：725-727.
[19] 顾文静.通阳祛瘀中药联合曲妥珠单抗治疗乳腺癌疗效及对血清CEA、CA153、CA724的影响[J].现代中西医结合杂志，2017，26（23）：2599-2601.
[20] 马隆波，王静，胡雪梅.生物治疗联合化疗与单纯化疗乳腺癌患者免疫功能的差异[J].滨州医学院学报，2015， 38（4）：263-265.
[21] 李杰宝.消癌顺气汤联合CAF化疗对147例乳腺癌患者T细胞亚群和血管内皮生长因子的影响及疗效分析[J].海南医学院学报，2015，21（3）：381-383.
[22] 李杰宝，张家衡.复方苦参注射液治疗乳腺癌术后化疗患者的临床疗效及其对外周血T细胞亚群的影响研究[J].中国医院药学杂志，2015，35（21）：1945-1949.
2019, Vol. 16 
京公网安备 11010502046598号